




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07F 9/40, A61K 31/66 C07F 9/58, 9/572, 9/6506 C07F 9/6571		A1	(11) International Publication Number: WO 92/22559 (43) International Publication Date: 23 December 1992 (23.12.92)
(21) International Application Number: PCT/US92/04013			(74) Agent: STEELE, Gregory, W.; Corporate Patents & Trademarks, The Upjohn Company, Kalamazoo, MI 49001 (US).
(22) International Filing Date: 21 May 1992 (21.05.92)			
(30) Priority data: 717,428 19 June 1991 (19.06.91)	US		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.
(60) Parent Application or Grant (63) Related by Continuation US 717,428 (CIP) Filed on 19 June 1991 (19.06.91)			
(71) Applicant (for all designated States except US): THE UP-JOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only) : JOHNSON, Roy, Allen [US/US]; 2122 Frederick Avenue, Kalamazoo, MI 49008 (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: DIALKYL (DIALKOXYPHOSPHINYL)METHYL PHOSPHATES AS ANTI-INFLAMMATORY AGENTS



(57) Abstract

Provided are novel dialkyl (dialkoxyphosphinyl)methyl phosphates of formula (IV) which are useful as anti-inflammatory and anti-arthritis agents. The compounds are synthesized from the reaction of tetraethyl oxiranylidenebisphosphonate and unsubstituted or alkyl-amines. Representative compounds include 2-(benzylamino)-1-(diethoxyphosphinyl)ethyl phosphonic acid diethyl ester, 1-(diethoxyphosphinyl)-2-[2'-(1',2',3',4'-tetrahydro)naphthylamino]ethyl phosphonic acid diethyl ester, 2-(3-fluorobenzylamino)-1-(diethoxyphosphinyl)ethyl phosphonic acid diethyl ester, and 5,5-dimethyl-2-[2-(3-fluorobenzyl)amino-1-[(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)oxy]ethyl]-1,3,2-dioxaphosphorinanane P,2-dioxide.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

**DIALKYL (DIALKOXYPHOSPHINYL)METHYL
PHOSPHATES AS ANTI-INFLAMMATORY AGENTS**

FIELD OF THE INVENTION

The invention provides novel phosphonate-phosphates, and acids and salts thereof, which
5 are useful as anti-inflammatory and anti-arthritis agents. The invention also provides a novel
process for the production of the compounds of the invention.

BACKGROUND OF THE INVENTION

There are various phosphonate-phosphates known in the art. Among these are the *gem*-
phosphonate-phosphates, structurally characterized by having one phosphonate group (-PO₃R₂) and
10 one phosphate group (-OPO₃R₂) bound to the same carbon atom.

The synthesis of known phosphonate-phosphates has been characterized. D. Brittelli, J.
Org. Chem., 1985, 50:1845-47, reports the formation of phosphinylethenyl phosphate from
chloracetyl chloride and trialkyl phosphites in ether. S.J. Fitch and K. Moedritzer, J. Amer.
Chem. Soc., 1962, 84:1876-79, report the formation of 1-hydroxy phosphonate-phosphates via a
15 base mediated isomeric rearrangement of the corresponding 1-hydroxy bisphosphonates. See also
A. Tromelin, et al., Phosphorous and Sulfur, 1986, 27:301-12. None of these references disclose
a utility for the compounds synthesized.

U.S. Patent 4,894,469 discloses a process for making halogenated phosphonate-phosphates
by reacting, first, alkylene oxide and phosphorus (III) chloride, and second, reacting the resulting
20 phosphate trialkylesters with a halogen-acyl halide. The product is said to be useful as a fire
retardant. L.M. Nguyen, et al., J. Med. Chem., 1987, 30:1426-33, report the synthesis of *gem*-
phosphonate phosphates having activities which alter lipid metabolism and plasma high density
lipoprotein cholesterol levels in rats. See also UK Patent 2,079,285. These compounds are
synthesized via the reaction of dialkyl acyl phosphonates with alkyl phosphite in the presence of
25 80-100 mol % dialkylamine.

Other bis-phosphorus compounds, particularly the bisphosphonates, reportedly have anti-
inflammatory activity, see e.g., U.S. Patent 4,746,654, Australian Patent 8551-534-A (Derwent
86-212293/33), or utilities in the treatment of abnormal calcium metabolism/deposition, see e.g.,
U.S. Patent 3,683,080, and DE 3,719,513 (Derwent 89-000580/01). However, no anti-
30 inflammatory properties have been reported for the *gem*-phosphonate-phosphates.

The general mode of synthesis of the phosphonate-phosphates has been well documented.
The typical procedure utilizes a reaction where the corresponding bisphosphonate undergoes
rearrangement in the presence of excess base to form the phosphonate-phosphate. See e.g.
Nguyen, et al, *J. Med. Chem.*, 1987, 30: 1426-1433. U.S. Patent 3,808,237, however, describes
35 a scheme in which a substituted ethane polyphosphonate is reacted with an epoxidizing agent to

produce the corresponding epoxy ethane diphosphonate. The epoxy ring thus formed is opened ("de-oxiranized") to form the ethane diphosphonate. The same or similar procedure is employed in the production of the various diphosphonates described in U.S. Patents 3,940,436, 3,944,599, 3,957,858, and 3,962,318.

5 The compounds of the invention differ from the prior art compounds in having an amino group at position 2 of the methylene moiety. The compounds of the invention are prepared by a novel process which comprises reacting an epoxy ethane diphosphonate with an amino compound. The synthesis of the epoxy ethane diphosphonate is known and is described in U.S. Patent 3,808,237.

10 The opening of epoxides by amines to form amino-alcohols is preceded in the literature, see for example, R.C. Larock, *Comprehensive Organic Transformations*, 1989, VCH Publishers, pp. 508-511. However, the opening of the epoxide tetramethyl oxiranylidenebisphosphonate by amines, followed by rearrangement to produce the compounds of the invention, has not been reported.

15 Known *gem*-phosphonate-phosphates reportedly display lipid-lowering and antiatherosclerotic activity. However, no anti-inflammatory properties have been reported for *gem*-phosphonate-phosphates.

20 This invention discloses novel *gem*-phosphonate phosphates useful as anti-inflammatories and in the treatment of arthritis. This invention also provides a process for the synthesis of the compounds of the invention.

INFORMATION DISCLOSURE

U.S. Patent 4,746,654 discloses bisphosphonates useful as anti-inflammatory agents. The compounds disclosed, however, are not related to the compounds of the invention.

25 Australian Patent 8551-534-A (Derwent 86-212293/33) discloses bisphosphonic acids and derivatives useful in treating abnormal calcium and phosphorous metabolism and are useful in treating arthritis. The compounds disclosed, however, are not structurally related to the compounds of the invention.

30 UK Patent 2 079 285 discloses bisphosphonic acids and phosphonic-phosphates, and derivatives thereof, useful as hypolipemic agents. The structures disclosed neither encompass the compounds of the invention nor does the patent disclose an anti-inflammatory utility.

A published European patent application, EP 320 455, discloses bisphosphonic acids and derivatives useful as regulators of calcium metabolism and as anti-inflammatories. The compounds disclosed, however, are not related to the compounds of the invention.

35 A published European patent application, EP 252 504, discloses bisphosphonic acids and derivatives thereof useful as regulators of calcium metabolism. The compounds disclosed,

however, are not related to the compounds of the invention.

L.M. Nguyen, et al, *J. Med. Chem.*, 1987, 30: 1426-33, report *gem*-phosphonate-phosphates which have anti-atherosclerotic potential. The compounds lack the amino group of the present invention.

5 U.S. Patent 4,894,469 discloses a process for making halogenated phosphonophosphoric acid and esters thereof useful as fire retardants. The compounds disclosed lack the amino group of the present invention.

U.S. Patent 3,808,237 discloses the synthesis of substituted epoxy ethane polyphosphates (bisphosphonates), which are useful as a starting material for the compounds of the invention. The 10 compounds are disclosed as having utility as fire retardants.

S.J. Fitch and K. Moedritzer, *J. Amer. Chem. Soc.*, 1962, 84:1876-79, report the formation of 1-hydroxy phosphonate-phosphates. However, the compounds lack the amino group of the present invention.

15 D. Brittelli, *J. Org. Chem.*, 1985, 50:1845-47, describes the synthesis of phosphonate-phosphates from chloroacetyl chloride. However, the compounds lack the amino group of the present invention.

A. Tromelin, et al, *Phosphorous and Sulfur*, 1986, 27:301-12, report isomerization and hydrolysis studies on hydroxy methylene diphosphonates. The resulting compounds, however, lack the amino group of the present invention.

20 M. Kanaan and R.Burgada, *Phosphorous and Sulfur*, 1988, 37: 217-29, disclose the synthesis of phosphonate-phosphates via the rearrangement reaction of bisphosphonates.

SUMMARY OF THE INVENTION

This invention provides a compound of formula IV (Chart A) wherein

R₁ is independent and selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, and
25 .C₆H₅;

adjacent R₁ taken together may be -CH₂(CH₂)_nCH₂- or -CH₂C(CH₃)₂CH₂-;

R₂ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, -CH₂CH=CH₂, -CH₂CH₂OH, -CH₂(CH₂)_nAr, -CH₂CH₂OCH₂Ar, -CH(C₆H₅)₂, and 1'- or 2'-(1',2',3',4'-tetrahydro)naphthylene;

30 R₃ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, -CO(CH₂)_mCH₃, -CO₂CH₂Ar, and -COAr;

n is 0, 1, or 2;

m is 0 thru 9;

Ar is selected from the group consisting of

35 (a) phenyl, 1- or 2-naphthyl, 3-indolyl, 2-, 3-, or 4-pyridinyl, or 1-imidazolyl,

-4-

- (b) phenyl optionally substituted with 1 thru 5 -F or -Cl,
- (c) phenyl optionally substituted with 1 thru 3 -Br, -I, -CF₃, -R₄, or -OR₄,
- (d) phenyl substituted with -COOR₄, -OCOR₄, -SO₂NH₂, -NHSO₂R₄, and

-NHCOR₄;

5 R₄ is C₁-C₅ alkyl;

provided, however, when R₁ is -C₂H₅, neither R₂ nor R₃ may be -C₃H₇;

and pharmaceutically acceptable salts thereof.

This invention also provides a process for making a compound of formula IV in which

R₁ is independent and selected from the group consisting of C₁-C₁₀ alkyl and -C₆H₅;

10 adjacent R₁ taken together may be -CH₂(CH₂)_nCH₂- or -CH₂C(CH₃)₂CH₂-;

R₂ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, -CH₂CH=CH₂, -CH₂CH₂OH, -CH₂(CH₂)_nAr, -CH₂CH₂OCH₂Ar, -CH(C₆H₅)₂, and 1'- or 2'-(1',2',3',4'-tetrahydro)naphthylene;

R₃ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl,

15 -CO(CH₂)_mCH₃, -CO₂CH₂Ar, and -COAr;

n is 0, 1, or 2;

m is 0 thru 9;

Ar is selected from the group consisting of

(a) phenyl, 1- or 2-naphthyl, 3-indolyl, 2-, 3-, or 4-pyridinyl, or 1-imidazolyl,

20 (b) phenyl optionally substituted with 1 thru 5 -F or -Cl,

(c) phenyl optionally substituted with 1 thru 3 -Br, -I, -CF₃, -R₄, or -OR₄,

(d) phenyl substituted with -COOR₄, -OCOR₄, -SO₂NH₂, -NHSO₂R₄, and

-NHCOR₄;

R₄ is C₁-C₅ alkyl;

25 provided, however, when R₁ is -C₂H₅, neither R₂ nor R₃ may be -C₃H₇,

comprising the steps of:

(a) reacting an epoxy ethane bisphosphonate compound of formula III with an amine at a temperature and for a period of time to form reaction products comprising substantially compound of formula IV;

30 (b) extracting the reaction products; and

(c) purifying the product via a chromatography procedure.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the invention are synthesized following techniques known by those skilled in the art of organophosphorous chemistry. For a general review see R. Engel, 1988, *Synthesis of Carbon-Phosphorous Bonds*, CRC Press, or alternatively, the required techniques may

35

be readily acquired by reference to standard laboratory manuals, for example, B.S. Furniss, et al, 1989, *Vogel's Textbook of Practical Organic Chemistry*, 5th Ed., Longman Scientific and Technical (publisher), all of which are incorporated by reference.

The synthesis of the compounds of formula IV is briefly described here and in more detail below. Referring to Chart A, paraformaldehyde in dialkyamine-methanol (formula Ia) is reacted with a methylene diphosphonate (formula Ib) to produce an ethyldene-1,1-phosphonate (formula II); these reactants (Ia and Ib), as well as suitable reaction conditions, are known by those skilled in the art. The compounds of formula II are also known, see e.g. U.S. Patents 4,894,469 and 3,808,237. The methylene diphosphonate (Ib) is substituted, i.e. R₁ is other than hydrogen. In addition, methylene (diethyl)diphosphonate is available from commercial sources. It is preferred that R₁ is ethyl (-CH₂CH₃). When adjacent R₁ are taken together it is preferred that it is -CH₂C(CH₃)₂CH₂-.

It is preferred that R₂ is hydrogen and that R₃ is either benzyl or -CH₂(3'-fluoro)benzyl.

The ethyldene-1,1-phosphonate (II) is subsequently reacted with alkaline hydrogen peroxide to produce the epoxide, oxiranylidenebisphosphonate (formula III). The epoxide is then treated with an amine to effect ring opening and substitution (formula IV). The amine may be substituted at either, or both, positions R₂ and R₃, or the amine may be unsubstituted. The amines are known in the art and are readily available from commercial sources.

The preparation of the acid (IV), i.e. where R₁ is hydrogen, may be achieved by exposure of the corresponding methyl or ethyl ester (IV) to trialkyl silyl halides (R_aR_bR_cSi-X), most commonly trimethyl silyl halide, followed by hydrolysis of the intermediately formed silyl ester (-SiR_aR_bR_c). (See e.g., C.E. McKenna, et al, *Tetr.Lett.*, 1977, 155, and R. Bittman, et al, *Chem.Phys.Lipids*, 1984, 34:201). Cleavage of these esters (IV) may also be achieved using cesium fluoride (CsF) or sodium iodide (NaI) following procedures known in the art.

When R₁ is trichloroethyl (-CH₂CCl₃), an alternative preparation of the acid form of IV may be accomplished by the use of a variety of reagents, for example, zinc, zinc amalgam, sodium naphthalide, cesium fluoride, and tetra-n-butyl ammonium fluoride. This procedure is known, see e.g., R.L. Letsinger and W.B. Lunsford, *J.Am.Chem.Soc.*, 1976, 98:3655, and K.K. Ogilvie, et al, *J.Am.Chem.Soc.*, 1977, 99:1277.

It is readily apparent that by making slight adjustments to the reaction parameters discussed here, and including the use of protecting groups when necessary, one skilled in the art may effect the mono-, di-, tri-, and tetra-acid forms of IV. In addition these and other known techniques are useful in the independent selection of esters for R₁, e.g. a compound of formula IV wherein R₁ consists of two methyl esters and two ethyl esters.

Any pharmaceutically acceptable salt may be employed to convert either the acid or ester

form of IV to the respective salt. The acid addition salts of IV may be prepared by reaction with an appropriate acid, e.g. hydrogen chloride, hydrobromic acid, tartaric acid, succinic acid, and the like. The base addition salts of the acid form of IV are prepared by reacting the acid with an appropriate base, for example, sodium, potassium, calcium, magnesium, ethanolamine, and the like. These addition reactions are well known in the art and require no special mention.

At the completion of any of the synthetic steps, the reaction mixture may be treated by conventional chemical processing and/or purification procedures, e.g. dilution, solvent partitioning, filtration, concentration, and cooling, to separate the products from the reactants. One or more solvents, in one or more extractions have been found useful for this purpose. For example, ether, 10 methylene chloride, and ethyl acetate are found to be useful for the separation and extraction following the ring opening and substitution by the amine. The compounds of the invention are oils or liquids and are thus readily separated by chromatographic methods known to be useful for this purpose by those skilled in the art of chemical purification and analysis. (See, for example, B.S. Furniss, et al, 1989, *Vogel's Textbook of Practical Organic Chemistry*, 5th Ed., Longman 15 Scientific and Technical (publisher)).

The compounds of the invention have pharmacological activity as anti-inflammatory or anti-arthritis agents. Thus, the compounds of the invention are useful in humans and animals in the treatment of diseases characterized by abnormal phosphate and/or calcium metabolism. These diseases include: osteoporosis, Paget's disease, periodontal disease, rheumatoid arthritis, 20 osteoarthritis, chondrocalcinosis, septic arthritis, neuritis, bursitis, soft tissue mineralization disorders, ankylosing spondylitis, atherosclerosis, multiple myeloma of bone, metastatic bone disease, chronic granulomatous diseases and mitral valve calcification. The compounds of the invention are also useful for treatment of inflammation in humans and animals.

The dialkyl (dialkoxyphosphinyl)methyl phosphates of the invention (IV) can be 25 administered orally, parenterally (intramuscularly, intravenously, subcutaneous or intraperitoneally), transdermally or intra-articularly or by suppository. The dose is about 0.01 gm/patient/day to about 1.0 gm/patient/day.

The *gem*-phosphonate-phosphates (IV) can be used alone or in combination with other pharmaceuticals as is known to those skilled in the art. The exact route of administration, dose, 30 frequency of administration, of a particular *gem*-phosphonate-phosphate (IV), depends on the particular disease or condition, the severity of the disease or condition, the age, general physical condition, weight, other clinical abnormalities etc. of the particular patient to be treated as is known to those skilled in the art.

To achieve maximum efficacy in the treatment of the diseases outlined above, intermittent 35 as well as continual daily therapy may be indicated, as is known to those skilled in the art. See,

for example, "Long-Term Effects of Dichloromethylene Diphosphonate in Paget's Disease of Bone", P. D. Dumas, et al., *J. Clin. Endocrinol. Metab.*, 54, 837 (1982); "Paget's Disease of Bone Treated in Five Days With AHPrBP(APD) Per Os", D. Thiebaud, et al., *J. Bone. Min. Res.*, 2, 45 (1987); "A Single Infusion of the Bisphosphonate AHPrBP(APD) as Treatment of Paget's 5 Disease of Bone" D. Thiebaud, et al., *The Am. J. Med.*, 85, 207 (1988); "A Double Blind Placebo-controlled Trial of Diphosphonate (APD) Therapy in Rheumatoid Arthritis - Preliminary Results", S. H. Ralston, et al., *Calcif. Int.*, 42, A23 (1988); "Treatment of Hypercalcemia of Malignancy With Intermittent Single Infusions of 3-Amino-1-hydroxypropylidene-1,1-bisphosphonate (APD)", D. Rischin, et al., *Aust. NZ. J. Med.*, 18, 736 (1988); "Reduced 10 Morbidity From Skeletal Metastases in Breast Cancer Patients During Long-Term Bisphosphonate (APD) Treatment" A. Th. van Holten-Verzantvoort, et al., *The Lancet* (10-31-87), p. 983; "Sclerosis of Lytic Bone Metastases After Disodium Aminohydroxypropylidene Bisphosphonate (APD) in Patients with Breast Carcinoma" A. R. Morton, et al., *British Med. J.*, 297, 772 (1988); "Two Year Follow-up of Bisphosphonate (APD) Treatment in Steroid Osteoporosis" I. R. Reid, 15 et al., *The Lancet* (11-12-88), p. 1144.

Definitions

The definitions which follow are for terms used throughout the specification and claims.
All temperatures are in degrees Centigrade.
TLC refers to thin-layer chromatography.
20 p-TSA refers to p-toluenesulfonic acid monohydrate.
TEA refers to triethylamine.
Brine refers to an aqueous saturated sodium chloride solution.
IR refers to infrared spectroscopy.
CMR refers to ^{13}C magnetic resonance spectroscopy; chemical shifts are reported in ppm
25 (δ) downfield from tetramethylsilane.
NMR refers to nuclear magnetic resonance spectroscopy; chemical shifts are reported in ppm (δ) downfield from tetramethylsilane.
 ϕ refers to phenyl (C_6H_5).
MS refers to mass spectrometry expressed as m/e or mass/charge unit.
30 $[\text{M} + \text{H}]^+$ refers to the positive ion of a parent plus a hydrogen atom.
EI refers to electron impact.
CI refers to chemical ionization.
FAB refers to fast atom bombardment.
Alkyl includes both linear and branched carbon-carbon chains.
35 Ether refers to diethyl ether.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological basis and to the manufacturing pharmaceutical chemist from a physical/chemical basis regarding composition, formulation, stability, patient acceptance, and bioavailability.

5 When solvent pairs are used, the ratios of solvents used are volume/volume (v/v).

Preparation 1 Tetraethyl ethyldene-1,1-diphosphate (II)

Paraformaldehyde (104.2 g) and diethylamine (50.8 g) are combined in methanol (2 L), warmed until clear, then treated with methylene bisphosphonic acid, tetraethyl ester (190.09 g) and refluxed for 18 hours. The sample is then concentrated, methanol added, the methanol removed by heat and reduced pressure, and toluene is added and removed by heat and reduced pressure. The residue is dissolved in toluene (1:l), treated with p-TSA (0.5 g) and refluxed through a Dean Stark trap for 18 hours. The sample is concentrated under reduced pressure with heat, dissolved in methylene chloride, washed twice with water, dried with magnesium sulfate, and concentrated under reduced pressure with heat. The sample is purified by distillation at reduced pressure to give 15 the title compound ($bp = 140^\circ$); MS (m/e) 300, 285, 273, 255, 245, 227, 217, 199, 192, 181, 163, 153 and 135; IR (neat) 2984, 2934, 2909, 1651, 1580, 1479, 1444, 1392, 1254, 1166, 1098, 1042, 1025, 974, 855, 813 and 800 cm^{-1} ; NMR (CDCl_3) δ 7.1, 6.7, 4.1 and 1.3 δ .

This compound is known, see published European Patent Application EP 221 611.

Preparation 2 Tetraethyl oxiranylidenebisphosphonate (III)

20 A solution of tetraethyl ethyldene-1,1-diphosphonate (Preparation 1, 1.510 g, 0.0050 mol) in 95% ethanol (5 ml) is treated with 30% aqueous hydrogen peroxide (1 ml) and sodium bicarbonate (0.424 g). The resulting mixture is stirred at room temperature for two hours, diluted with brine and extracted with methylene chloride (2x). The combined organic extracts are dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give tetraethyl 25 oxiranylidenebisphosphonate tetraethyl oxiranylidenebisphosphonate as a clear, colorless oil (1.472 g, 0.00465 mol). No further purification of the product is performed. IR (neat): 1260, 1026, 1023, and 978 cm^{-1} ; ^1H NMR (CDCl_3 , TMS) δ 4.28-4.19, 3.28, 1.37; ^{13}C NMR (CDCl_3) δ 63.44, 49.36, 47.24, 16.17; ^{31}P NMR (CDCl_3) δ 13.85; Mass spectrum: 316.0840 m/e, $\text{C}_{10}\text{H}_{22}\text{O}_7\text{P}_2$ requires 316.0841.

30 Preparation 3 2,2'-(1,1-Oxiranyl)bis[5,5-dimethyl-1,3,2-dioxaphosphorinane] 2,2'-dioxide (III)
1,3,2-dioxaphosphorinane, 2,2'-ethyldene bis(5,5'-dimethyl)-2,2'-dioxide is prepared following the procedure described in International Application PCT/US91/05554 (publication WO92/03451). A solution of 1,3,2-dioxaphosphorinane, 2,2'-ethyldene bis(5,5'-dimethyl)-2,2'-dioxide (1.146 g, 0.0035 mole) in methylene chloride (7 mL) is cooled to 0-5° by means of an ice-water bath. This solution is treated with hydrogen peroxide (0.7 mL, 30% solution) in a single

lot, followed by solid sodium bicarbonate (0.40 g, 0.0048 mole). The mixture is allowed to stir overnight at room temperature. The mixture is diluted with methylene chloride and water and the layers separated. The aqueous layer is extracted with methylene chloride(2x). The combined layers are dried (MgSO_4), filtered and concentrated *in vacuo* to obtain 1.024 g (86% yield) of the title compound as a white solid. A portion of the crude material is crystallized from ethyl acetate to obtain colorless crystals: mp 143.3-144.3° dec. ^1H NMR (CDCl_3/TMS) δ 4.58 (d, $J = 10.9$ Hz, 2H, $\text{CH}_2\text{OP(O)}$), 4.43 (d, $J = 10.6$ Hz, 2H, $\text{CH}_2\text{OP(O)}$), 4.06-3.97 (m, 4H, $\text{CH}_2\text{OP(O)}$), 3.34 (t, $J = 5.5$ Hz, 2H, CH_2), 1.31 (s, 3H, CH_3), 0.94 (s, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 78.82 (d, $J = 107.9$ Hz, $\text{CH}_2\text{OP(O)}$), 49.25 (t, $J = 175.2$ Hz, P(O)CP(O)), 48.52 ($\text{CH}_2\text{CP(O)}$), 32.60 ($\text{C}(\text{CH}_3)_2$), 22.09, 20.54; ^{31}P NMR (CDCl_3) δ 4.426.

Anal. Calcd. for $\text{C}_{12}\text{H}_{22}\text{O}_7\text{P}_2$: C, 42.36; H, 6.52. Found: C, 42.41; H, 6.66.

Example 1 2-(Cyclohexylamino)-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester

A solution of cyclohexylamine (3.6 ml, 3.14 g, 0.0316 mol) in ether (3 ml) is mixed with tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.066 g, 0.00632 mol) and stirred at room temperature for 24 hours. Additional cyclohexylamine (2.601 g, 0.026 mol) is added and stirring continued until TLC (25% acetonitrile in ethyl acetate, 50% acetone in methylene chloride) reveals that most of the starting epoxide is consumed. The reaction mixture is diluted with ether (60 ml) and brine (60 ml) is added. The layers are separated and the aqueous layer is extracted with ether (3 x 60 ml), methylene chloride, and ethyl acetate. The combined extracts are dried (magnesium sulfate), filtered, and concentrated to give 3.233 g of crude product. Flash chromatography (400g silica gel) of the crude product is carried out eluting with increasing proportions (from 0 to 10%) of 10% ammonium hydroxide/methanol in acetonitrile. The reactions containing the desired product are combined to give 1.046 g (0.00251 mol, 40%) of 2-(cyclohexylamino)-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester as a colorless oil; ^1H NMR (CDCl_3 , TMS) δ 4.80-4.70, 4.26-4.13, 3.21-3.00, 2.52-2.45, 1.89-1.59, 1.38-1.02; ^{13}C NMR (CDCl_3) δ 72.46, 64.19, 62.80, 55.67, 46.57, 33.14, 32.73, 25.86, 24.66, 24.59, 16.31-15.84; ^{31}P NMR (CDCl_3) δ 17.61, -1.89; Mass spectrum 416.1968, $\text{C}_{16}\text{H}_{35}\text{NO}_7\text{P}_2$ requires 416.1967. Anal. Calcd. for $\text{C}_{16}\text{H}_{35}\text{NO}_7\text{P}_2$: C, 46.26; H, 8.49; N, 3.37. Found: C, 45.96; H, 8.58; N, 3.59.

Example 2 1-(Diethoxyphosphinyl)-2-[(2'-hydroxy)ethylamino]ethyl phosphoric acid diethyl ester

A mixture of tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.106 g, 0.0066 mol) and ethanolamine (7, 4.0 ml, 4.07 g, 0.066 mol) is stirred at room temperature for 18 hours after which TLC (10% methanol in acetone) revealed that the reaction is complete. Ether (60 ml) and brine (60 ml) are added to the reaction mixture and the layers are separated. The aqueous layer

is extracted further with ether (3 x 60 ml), ethyl acetate, and methylene chloride. The combined organic extracts are dried (magnesium sulfate), filtered, and concentrated to give 1.173 g of crude product. This material is purified by flash chromatography (192 g silica gel, 45 ml fractions) using 5% of 10% NH₄OH/CH₃OH in methylene chloride for elution. Fractions 33-58 contained the desired product and are pooled to yield 0.665 g (0.00176 mol, 26%) of 1-(diethoxyphosphinyl)-2-[2'-hydroxyethylamino]ethyl phosphoric acid diethyl ester as a colorless oil; ¹H NMR (CDCl₃, TMS) δ 4.78-4.70, 4.26-4.12, 3.63, 3.15, 3.13, 2.93-2.86, 2.81-2.74, 1.38-1.33; ¹³C NMR (CDCl₃) δ 72.02, 64.28, 62.96, 60.45, 50.40, 49.12, 16.27-15.67; ³¹P NMR (CDCl₃) δ 17.58, -1.87; Mass spectrum 378.1445, C₁₂H₂₉NO₈P₂ requires 378.1447.

10 Example 3 2-(Benzylamino)-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester
A mixture of tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.085 g, 0.00632 mol) and benzylamine (3.40 g, 0.0316 mol) in ether (4 ml) is stirred at room temperature for 18 hours, after which TLC (50% ethyl acetate in methanol, 50% acetone in hexane) indicates that some epoxide remained unreacted. Additional benzylamine (2.94 g, 0.0274 mol) is added and stirring continues another 24 hours. Volatiles are removed *in vacuo* and the residue is chromatographed (flash, 400 g, silica gel, 45 ml fractions) using 2.5 to 5% of 10% NH₄OH/CH₃OH in methylene chloride to elute the column. The desired product eluted in fractions 94-104 which are pooled to give 10 (1.069 g, 0.00253 mol, 40%) as a colorless oil; ¹H NMR (CDCl₃, TMS) δ 7.34-7.23, 4.87-4.77, 4.24-4.07, 3.88, 3.78, 3.14-3.09, 1.36-1.24; ¹³C NMR (CDCl₃) δ 139.80, 128.36, 128.14, 126.98, 72.29, 64.26, 62.99, 53.07, 49.24, 16.49-15.99; ³¹P NMR (CDCl₃) δ 17.55, -1.90; Mass spectrum 424.1655, C₁₇H₃₁NO₇P₂ requires 424.1654.

20 Example 4 1-(Diethoxyphosphinyl)-2-[2'-(1',2',3',4'-tetrahydro)naphthylamino]ethyl phosphoric acid diethyl ester

A mixture of tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.015 g, 0.00637 mol) and 1,2,3,4-tetrahydronaphth-2-ylamine (2.142 g, 0.0146 mol) is stirred at room temperature for two days. Additional 1,2,3,4-tetrahydronaphth-2-ylamine (1.017 g, 0.0032 mol) is added and the mixture stirred another eight days. The mixture is chromatographed (flash, 200 g silica gel) using 10% acetone in chloroform for elution of the column. The product, 1-(diethoxyphosphinyl)-2-[2'-(1',2',3',4'-tetrahydro)naphthylamino]ethyl phosphoric acid diethyl ester (1.262 g, 0.00272 mol, 42%) is obtained as a viscous oil; ¹H NMR (CDCl₃, TMS) δ 7.08, 4.84-4.72, 4.23-4.09, 3.32-3.10, 3.05-2.90, 2.85-2.70, 2.63-2.55, 2.10-1.95, 1.70-1.50, 1.38-1.24; ¹³C NMR (CDCl₃) δ 135.96, 134.83, 129.08, 128.42, 125.52, 125.42, 72.48, 64.15-63.94, 62.95-62.56, 52.40, 52.31, 46.90, 46.85, 46.81, 36.43, 35.96, 29.31, 28.56, 27.50, 27.22; ³¹P NMR (CDCl₃) δ 17.76, -2.00; Mass spectrum 464.1975 m/e, C₂₀H₃₅NO₇P₂ requires 464.1967.

35 Example 5 2-[(3'-Fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid, diethyl

ester

A solution of 3-fluorobenzylamine (2.171 g, 0.0173 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 1.097 g, 0.0034 mole) in ether (2 mL) is stirred at room temperature for 24 hours. TLC (4% methanol in methylene chloride) reveals that the starting material (epoxide) is consumed. The solvent is removed *in vacuo* and the remaining residue is chromatographed twice (flash, 0.040-0.063 mm silica gel, 2% methanol in methylene chloride) to give 2-[*(3'*-fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester (0.344 g, 0.00078 mole, 23%) as a colorless oil. ^1H NMR (CDCl_3/TMS) δ 7.30-7.23, 7.11-7.06, 6.96-6.89, 4.83-4.77, 4.25-4.08, 3.88, 3.78, 3.10, 1.94, 1.36-1.26; ^{13}C NMR (CDCl_3) δ 163.0, 142.5, 129.6, 123.4, 114.6, 113.6, 72.0, 64.2-64.1, 63.0-62.8, 52.3, 49.0, 18.0-15.8; ^{31}P NMR (CDCl_3) δ 17.47, -1.95; Mass Spectrum: 441.1472 ($\text{C}_{17}\text{H}_{30}\text{FNO}_7\text{P}_2$ requires 441.1481); Anal. Calc. for $\text{C}_{17}\text{H}_{30}\text{FNO}_7\text{P}_2$: C, 46.26; H, 6.85; N, 3.17. Found: C, 46.22; H, 6.96; N, 3.16.

Example 6 1-(Diethoxyphosphinyl)-2-[*(3'*-pyridyl)methylamino]ethyl phosphoric acid diethyl ester

A solution of 3-(aminomethyl)pyridine (3.406 g, 0.0315 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.001 g, 0.0063 mole) in ether (6 mL) is stirred at room temperature for 24 hours. TLC (7% of a 10% $\text{NH}_3/\text{CH}_3\text{OH}$ solution in methylene chloride) indicates that some epoxide remains unreacted. The solvent is removed *in vacuo* and the remaining residue is chromatographed (flash, 0.040-0.063 mm silica gel, 23 cm height, 8 cm wide, 4% of a 10% $\text{NH}_3/\text{CH}_3\text{OH}$ in methylene chloride, 30 mL fractions). Fractions 104 to 132 are pooled and concentrated to give 1-(diethoxyphosphinyl)-2-[*(3'*-pyridyl)methylamino]ethyl phosphoric acid diethyl ester (1.216 g, 0.0029 mole, 45%) as a yellow oil; ^1H NMR (CDCl_3/TMS) δ 8.53, 8.46, 7.68, 7.21, 4.82-4.72, 4.21-4.04, 3.87, 3.75 3.08, 1.95, 1.36-1.22; ^{13}C NMR (CDCl_3) δ 149.39, 148.24, 135.52, 134.92, 123.07, 71.82, 64.09-63.95, 62.84-62.63, 50.08, 48.97, 16.20-15.69; ^{31}P NMR (CDCl_3) δ 17.28, -2.03; Mass Spectrum: 424.1529 ($\text{C}_{16}\text{H}_{30}\text{N}_2\text{O}_7\text{P}_2$ requires 424.1528); Anal. Calc. for $\text{C}_{16}\text{H}_{30}\text{N}_2\text{O}_7\text{P}_2$: C, 45.29; H, 7.13; N, 6.60. Found: C, 45.38; H, 7.24; N, 6.65.

Example 7 1-(Diethoxyphosphinyl)-2-[2'-*(3'*-indolyl)ethylamino]ethyl phosphoric acid diethyl ester

A solution of tryptamine (5.06 g, 0.0315 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.001 g, 0.0063 mole) in methanol is stirred at room temperature for 24 hours. TLC (7% of a 10% $\text{NH}_3/\text{CH}_3\text{OH}$ solution in methylene chloride) reveals that starting material is consumed. The solvent is removed *in vacuo* and the remaining residue is chromatographed (flash, 0.040-0.063 mm, silica gel, 24 cm height, 8 cm wide, 2% to 5% of a 10% $\text{NH}_3\text{CH}_3\text{OH}$ solution in methylene chloride, 40 mL fractions). Fractions 118 to 156 are pooled and concentrated to give

-12-

1-(diethoxyphosphinyl)-2-[2'-(3"-indolyl)ethylamino]ethyl phosphoric acid diethyl ester (1.672 g, 0.0036 mole, 57%) as a dark yellow oil. ^1H NMR (CDCl_3/TMS) δ 8.16, 7.61, 7.36-7.34, 7.20-7.04, 4.80-4.72, 4.21-4.02, 3.16-3.11, 3.09-2.92, 1.37; ^{13}C NMR (CDCl_3) δ 136.08, 127.18, 121.73, 121.64, 118.93, 118.54, 113.49, 110.84, 72.14, 64.01-63.89, 62.81-62.58, 49.60, 49.20, 25.52, 16.23-15.73; ^{31}P NMR (CDCl_3) δ 17.75, -2.16; Anal. Calc. for $\text{C}_{20}\text{H}_{34}\text{N}_2\text{O}_7\text{P}_2$: C, 50.42; H, 7.19; N, 5.88; Found: C, 50.29; H, 7.21; N, 5.89.

5 Example 8 2-[Acetyl(3'-fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester

A solution of 2-[3'-fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid, 10 diethyl ester (Example 5, 0.120 g, 0.272 mmole) in water (0.08 mL) and acetic acid (0.081 mL) is prepared at room temperature and is cooled to 0-5°C by means of an ice-water bath. The solution is treated with acetic anhydride (0.03 g, 0.30 mmole) and is stirred for half an hour. The low temperature bath is removed and the mixture is stirred for an hour at room temperature. Volatiles are removed under high vacuum to obtain 2-[acetyl(3'-fluoro)benzylamino]-1- 15 (diethoxyphosphinyl)ethyl phosphoric acid diethyl ester as a colorless oil in quantitative yield. ^1H NMR (CDCl_3/TMS) δ 7.37-7.42, 7.10-6.85, 5.17, 5.06, 4.90, 4.75, 4.61, 4.26-4.09, 3.86-3.66, 3.52-3.40, 2.23, 2.11, 1.39-1.26; ^{13}C NMR (CDCl_3) δ 171.88, 177.15, 163.28, 139.49, 130.61, 130.17, 123.83, 121.77, 115.06, 114.57, 114.46, 113.21, 70.57, 69.80, 64.69-63.13, 52.91, 47.36-46.72, 21.78, 16.49-16.10; ^{31}P NMR (DMSO) δ 21.21, 20.93, -2.83, -2.63; Mass Spectrum: 483.1574 ($\text{C}_{19}\text{H}_{32}\text{FNO}_8\text{P}_2$ requires 483.1587).

20 Example 9 1-(Diethoxyphosphinyl)-2-[3'-(1'-imidazolyl)propylamino]ethyl phosphoric acid diethyl ester

A solution of 1-(3-aminopropyl)imidazole (3.96 g, 0.0317 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.003 g, 0.0063 mole) in ether (4 mL) and methanol (4 mL) is stirred at room temperature for 24 hours. TLC (15% of a 10% $\text{NH}_3/\text{CH}_3\text{OH}$ solution in methylene chloride) indicates that some epoxide remains unreacted. The reaction mixture is allowed to stir for another 24 hours and is placed in the refrigerator for 72 hours. The solvent is removed *in vacuo* and the remaining residue is chromatographed (flash, 0.040-0.063 mm silica gel, 28 cm height, 8 cm wide, 3% of a 10% $\text{NH}_3/\text{CH}_3\text{OH}$ solution in methylene chloride) to give 25 1.167 g of a slightly impure product. A second chromatography is performed (8% to 24% methanol in ethyl acetate and 5% of a 10% $\text{NH}_3/\text{CH}_3\text{OH}$ solution in ethyl acetate) to give 1-(diethoxyphosphinyl)-2-[3'-(1'-imidazolyl)propylamino]ethyl phosphoric acid diethyl ester (1.001 g, 0.0023 mole, 36%) as a dark yellow oil. ^1H NMR (CDCl_3/TMS) δ 7.49, 7.05, 6.93, 4.78-4.68, 4.25-4.11, 4.06, 3.07, 2.68, 2.54, 1.91, 1.77, 1.38-1.32; ^{13}C NMR (CDCl_3) δ 137.30, 129.43, 118.89, 72.11, 64.36, 63.15-62.94, 49.80, 45.27, 44.35, 31.19, 16.55-16.09; ^{31}P NMR 30 35

(CDCl₃) δ 17.40, -1.95; Anal. Calc. for C₁₆H₃₃N₃O₇P₂: C, 43.54; H, 7.53; N, 9.52. Found: C, 43.23; H, 7.38; N, 9.65.

Example 10 1-(Diethoxyphosphinyl)-2-(2'-propen-1'-ylamino)ethyl phosphoric acid diethyl ester

5 A solution of allylamine (2.86 g, 0.05 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 3.00 g, 0.0095 mole) in methanol (20 mL) is cooled to 0-5°C by means of an ice-water bath. The mixture is stirred till the low temperature bath expires and then stirring is continued overnight at room temperature. TLC (10% of a 10% NH₃/CH₃OH solution in methylene chloride) indicates that starting material is consumed. The solvent and excess of 10 allylamine are removed *in vacuo* to give 3.621 g of crude material from which 1.025 g is chromatographed (flash, 160 g, 0.0403-0.063 mm silica gel, 4 cm wide, 20% to 30% acetone in methylene chloride) to give 1-(diethoxyphosphinyl)-2-(2'-propen-1'-ylamino)ethyl phosphoric acid diethyl ester (0.635 g, 63% overall yield) as a clear oil. ¹H NMR (CDCl₃) δ 5.87, 5.19, 5.09, 4.83-4.72, 4.26-4.12, 3.34, 3.24, 3.12-3.07, 1.38-1.32; ¹³C NMR (CDCl₃) δ 136.22, 116.00, 15 72.15, 64.23-64.05, 62.95-62.48, 51.40, 48.98, 16.38-15.90; ³¹P NMR (CDCl₃) δ 17.30, -2.04; Anal. Calc. for C₁₃H₂₉NO₇P₂: C, 41.82; H, 7.83; N, 3.75. Found: C, 42.14; H, 7.84; N, 3.58.

Example 11 2-[Benzylxyformyl(2'-propen-1'-yl)amino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester

A solution of allylamine (2.86 g, 0.050 mole) is cooled to 0-5°C by means of an ice-water 20 bath and is treated with tetraethyl oxiranylidenebisphosphonate (Preparation 2, 3.00 g, 0.0095 mole). The mixture is stirred until the low temperature bath expires and then it is stirred overnight at room temperature. The solvent and excess allylamine are removed *in vacuo* and the residue is dissolved in water (70 mL). A solution of sodium hydroxide (4.75 mL, 2.0 N solution in water, 0.0095 mole) is slowly added followed by cooling the mixture to 0-5°C. After 20 minutes, the 25 mixture is simultaneously treated with benzylchloroformate (2.269 g, 0.0133 mole) in tetrahydrofuran (70 mL) and a solution of sodium hydroxide (2.38 mL, 4.0 N solution in water, 0.0095 mole). The mixture is stirred for 45 minutes after the addition is completed. TLC (30% acetone in methylene chloride) indicates that starting material is consumed. The mixture is diluted with ether and layers are separated. The aqueous layer is extracted with ether (2x). The combined 30 ether extracts are dried (magnesium sulfate), filtered and concentrated. The crude is chromatographed (flash, 300 g, 0.040-0.063 mm silica gel, 5% to 30% acetone in methylene chloride) to give 2-[benzyloxyformyl(2'-propen-1'-yl)amino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester (2.716 g, 0.0054 mole, 56%) as a clear oil. ¹H NMR (CDCl₃) δ 7.42-7.30, 5.87-5.70, 5.70-5.10, 5.05-5.87, 4.29-3.90, 3.72-3.65, 1.38-1.26; ¹³C NMR (CDCl₃) 35 δ 155.91, 155.42, 136.14, 132.82, 128.18, 127.81, 127.74, 127.54, 117.17, 116.60, 71.72-69.18,

67.26, 67.00, 63.91, 62.87, 50.24, 50.04, 47.16, 46.10, 16.14-15.73; ^{31}P NMR (CDCl_3) δ 16.43, 16.27, -1.75, -2.26; Anal. Calc. for $\text{C}_{21}\text{H}_{35}\text{NO}_7\text{P}_2$: C, 49.71; H, 6.95; N, 2.76. Found: C, 49.82; H, 7.03; N, 2.71.

Example 12 1-(Diethoxyphosphinyl)-2-(diphenylmethylamino)ethyl phosphoric acid diethyl ester

A solution of diphenylaminomethane (5.86 g, 0.032 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 2.026 g, 0.064 mole) in methanol (10 mL) is stirred at room temperature for 24 hours. TLC (50% ethyl acetate in hexane) indicates some epoxide remains unreacted. Stirring is continued for another 24 hours. The solvent is removed *in vacuo* and the remaining residue is chromatographed (flash, 0.040-0.063 mm silica gel 50% ethyl acetate in hexane, 50% ethyl acetate in hexane plus 2% methanol) to obtain 2.063 g of the desired product further chromatographed (flash, 0.040-0.063 mm silica gel, 30% acetone in hexane) to give 1-(diethoxyphosphinyl)-2-(diphenylmethylamino)ethyl phosphoric acid diethyl ester (0.728 g, 0.0016 mole, 55% overall yield) as a pale yellow oil. ^1H NMR (CDCl_3) δ 7.43-7.39, 7.30-7.25, 7.21-7.16, 4.91-4.70, 4.21-3.98, 3.06, 2.25, 1.34-1.26, 1.17; ^{13}C NMR (CDCl_3) δ 143.55, 143.27, 128.39, 127.23, 127.16, 126.98, 72.48, 66.39, 64.20-64.08, 62.96-62.80, 47.82, 16.35-15.16; ^{31}P NMR (CDCl_3) δ 17.44, -1.90; Mass Spectrum: 500.2015 ($\text{C}_{23}\text{H}_{35}\text{NO}_7\text{P}_2$ requires 500.1967); Anal. Calc. for $\text{C}_{23}\text{H}_{35}\text{NO}_7\text{P}_2$: C, 55.31; H, 7.06; N, 2.80. Found: C, 55.08; H, 7.05; N, 2.47.

Example 13 (1 R ,1' R)-1-(Diethoxyphosphinyl)-2-[(1'-phenyl)ethylamino]ethyl diethyl ester

A solution of (R)-(+) -1-phenylethylamine (6.06 g, 0.05 mole) and tetraethyl oxiranylidenebisphosphonate (Preparation 2, 3.161 g, 0.010 mole) in methanol (20 mL) is stirred at room temperature for 72 hours. TLC (30% acetone in hexane) indicates that starting material is consumed. Solvent is removed *in vacuo* to obtain 2.36 g of crude material. The crude is chromatographed (flash, 0.040-0.063 mm silica gel 2% methanol in a 50% acetone/hexane) three times to obtain the diastereomeric mixture (1.04 g) as a pale yellow oil. Partial separation of the diastereoisomers is achieved: less polar diastereoisomer (0.534 g, $[\alpha]_D +19.5^\circ$, (c = 1.10, ethanol)) as a pale yellow oil and more polar diastereoisomer (0.205 g, $[\alpha]_D +24.5$, c = 0.950, ethanol) also an oil. The overall yield of the reaction is 43%.

Mixture of diastereoisomers: ^1H NMR (CDCl_3) δ 7.32-7.22, 4.84-4.69, 4.20-4.08, 4.38-3.78, 2.98-2.92, 1.36-1.28; ^{13}C NMR (CDCl_3) δ 144.88, 144.57, 128.10, 126.65, 126.39, 126.30, 72.46, 71.94, 64.02, 62.88, 57.51, 56.79, 47.40, 47.23, 24.20, 23.87, 16.15-15.68; ^{31}P NMR (CDCl_3) δ 17.72-17.42, -1.85- -2.15; Anal. Calc. for $\text{C}_{18}\text{H}_{33}\text{NO}_7\text{P}_2$: C, 49.43; H, 7.61; N, 3.20. Found: C, 49.60; H, 7.70; N, 3.15.

Less polar isomer: Rf 0.53 (develop plate first in 30% acetone/hexane, then in 2%

methanol in 98% (50% acetone/hexane)); ^1H NMR (CDCl_3) δ 7.32-7.22, 4.80-6.99, 4.21-4.05, 3.79, 2.95, 1.36-1.26; ^{13}C NMR (CDCl_3) δ 145.01, 128.20, 126.74, 126.41, 72.57, 64.03-63.91, 62.83-62.58, 57.62, 47.51, 23.97; ^{31}P NMR (CDCl_3) δ 17.66, -2.01; Mass Spectrum: 437.1723 ($\text{C}_{18}\text{H}_{33}\text{NO}_7\text{P}_2$ requires 437.1732).

5 More polar isomer: Rf 0.47 (develop plate first in 30% acetone/hexane, then in 2% methanol in 98% (acetone/hexane)); ^1H NMR (CDCl_3) δ 7.32-7.22, 4.83-4.72, 4.20-4.09, 3.84, 2.95-2.90, 1.36-1.26; ^{13}C NMR (CDCl_3) δ 144.81, 128.35, 126.89, 126.61, 72.19, 64.26-64.10, 62.95-62.71, 57.03, 47.46, 24.41; ^{31}P NMR (CDCl_3) δ 17.55, -1.94; Mass Spectrum: 437.1732 ($\text{C}_{18}\text{H}_{33}\text{NO}_7\text{P}_2$ requires 437.1732).

10 Example 14 5,5-Dimethyl-2-[2-(3-fluorobenzyl)amino-1-[(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)oxy]ethyl]-1,3,2-dioxaphosphorinane P,2-dioxide

3-Fluorobenzylamine (1.10 g, 0.0088 mole) in methanol (6 mL) is treated with 2,2'-(1,1-oxiranyl)bis[5,5-dimethyl-1,3,2-dioxaphosphorinane] 2,2'-dioxide (Preparation 3, 1.00 g, 0.00294 mole) and allowed to stir for 16 hours. The solvents are removed *in vacuo* and the remaining oil 15 is allowed to crystallize over a mixture of acetone and hexane. The crystals (monohydrated product) are collected and the filtrate is concentrated to 0.951 g of crude material. The crude is chromatographed over flash silica gel (100 g, 0.040-0.063 mm) and is eluted with 4% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ to obtain 0.515 g (0.0011 mole, 38%) of a clear thick oil which solidifies upon standing at 4-5°C. The solid is crystallized from hexane to obtain a first crop of the title 20 compound (0.262 g., mp 110°C). ^1H NMR (CDCl_3/TMS) δ 7.31-7.23 (m, 1H, ArH), 5.01 (m, 1H, CHO), 4.29-4.18 (m, 9H, $\text{CH}_2\text{OP(O)}$, CHAr), 3.80 (d, $J = 13.6$ Hz, 1H, CHAr), 3.22-3.16 (m, 2H, P(O)CHCH₂NH), 1.25 (s, 3H, CH₃), 1.22 (s, 3H, CH₃), 0.98 (s, 3H, CH₃), 0.90 (s, 3H, CH₃); ^{13}C NMR (CDCl_3) δ 162.73 (d, $J = 244.2$ Hz, C-F), 142.23 (d, $J = 6.7$ Hz, Ar), 129.58 (d, $J = 7.9$ Hz, Ar), 123.43 (d, $J = 2.5$ Hz, Ar), 114.64 (d, $J = 21.3$ Hz, Ar), 113.6 (d, 25 $J = 21.1$ Hz, Ar), 78.79-76.85 (m, P(O)OCH₂), 70.82 (d, $J = 160.5$, 7.5 Hz, P(O)CHOP(O)), 52.24 (CH₂Ph), 48.66 (CH₂CH), 32.32 (d, $J = 7.7$ Hz, C(CH₃)₂), 31.89 (d, $J = 5.8$ Hz, C(CH₃)₂), 21.55, 21.37, 20.66, 20.04; ^{31}P NMR (CDCl_3) δ 11.98 (d, $J_{\text{PCOP}} = 22.2$ Hz, P(O)CHOP(O)), -6.88 (d, $J_{\text{PCOP}} = 22.2$ Hz, P(O)CHOP(O)).

Anal. Calcd. for $\text{C}_{19}\text{H}_{30}\text{FNO}_7\text{P}_2$: C, 49.04; H, 6.50; N, 3.01; P, 13.31. Found: C, 49.22; H, 30 6.47; N, 3.07; P, 13.44.

Example 15 5,5-Dimethyl-2-[2-(2-phenyl)ethylamine-1-[(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)oxy]ethyl]-1,3,2-dioxaphosphorinane P,2-dioxide


A solution of 2,2'-(1,1-Oxiranyl)bis[5,5-dimethyl-1,3,2-dioxaphosphorinane] 2,2'-dioxide (Preparation 3, 2.00 g, 0.0059 mole) in acetonitrile (25 ml) is treated with phenethylamine (0.784 35 g, 0.0065 mole) followed by potassium carbonate (0.40 g, 0.0030 mole) at room temperature and

-16-

it is stirred for 16 hours. The mixture is diluted with dichloromethane and washed with brine. The aqueous layer is washed with dichloromethane (2 times). The combined organic layers are dried (magnesium sulfate), filtered and concentrated to obtain 3.023 g of crude material. The crude material is chromatographed (flash, 0.042-0.060 mm silica gel, 300 g, 1 to 3% methanol/ethyl acetate, 500 ml forerun, 228 fractions, 35 to 30 ml) to obtain 1.860 g of a slightly impure desired product. A second chromatography (flash, 0.042-0.060 mm silica gel, 138 g, 4% methanol/dichloromethane, 100 ml forerun) is necessary to obtain 1.049 g (0.0023 mole, 39%) of 5,5-dimethyl-2-[2-(2-phenyl)ethyl]amine-1-[(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)oxy]ethyl]-1,3,2-dioxaphosphorinane P,2-dioxide as a pale thick oil. ^1H NMR (CDCl_3 ITMS) δ 7.31-7.19 (M, 5H, ArH), 5.02-4.93 (M, 1H, P(O) CHOP(O)), 4.26-4.22 (M, 2H, $\text{CH}_2\text{OP}(\text{O})$), 4.15-4.09 (M, 2H, $\text{CH}_2\text{OP}(\text{O})$), 4.03-3.79 (M, 4H, $\text{CH}_2\text{OP}(\text{O})$), 3.24-3.19 (M, 2H, $\text{CH}_2\text{CHOP}(\text{O})$), 3.04-2.96 (M, 1H, $\underline{\text{CH}}\text{HCH}_2\text{Ar}$), 2.93-2.89 (M, 1H, $\underline{\text{CH}}\text{HCH}_2\text{Ar}$), 2.84-2.80 (M, 2H, CH_2Ar), 1.24 (S, 3H, CH_3), 1.23 (S, 3H, CH_3), 0.96 (S, 3H, CH_3), 0.87 (S, 3H, CH_3); ^{13}C NMR (CDCl_3) δ 139.87, 128.79, 128.43, 126.10, 78.09 (t, $J=6.15$, CH_2O), 71.01 (dd, $J=7.5$, 160.8 Hz, P(O)CHOP(O), 50.55, 49.46, 36.41, 32.55 (d, $J=7.5$ Hz, $\underline{\text{C}}(\text{CH}_3)_2$), 32.09 (d, $J=5.6$ Hz, $\underline{\text{C}}(\text{CH}_3)_2$), 21.85, 21.65, 20.90, 20.28; ^{31}P NMR (CDCl_3) δ 11.87 (d, $J_{\text{PCOP}}=22.61$ Hz, P(O)CHOP(O)), -7.01 (d, $J_{\text{PCOP}}=22.40$ Hz, P(O)CHOP(O)). Anal. Calcd for $\text{C}_{20}\text{H}_{33}\text{O}_7\text{NP}_2$: C, 52.06; H, 7.21; N, 3.04. Found: C, 51.77; H, 7.33; N, 3.09

-17-


CHART A




-18-

Chart A (continued)

5



10



IV


15

20

CLAIMS

1. A compound of formula

5



10

15

wherein

R_1 is independent and selected from the group consisting of hydrogen,

C_1-C_{10} alkyl, and $-C_6H_5$;

adjacent R_1 taken together may be $-CH_2(CH_2)_nCH_2-$ or $-CH_2C(CH_3)_2CH_2-$;

20 R_2 is selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_7 cycloalkyl, $-CH_2CH=CH_2$, $-CH_2CH_2OH$, $-CH_2(CH_2)_nAr$, $-CH_2CH_2OCH_2Ar$, $-CH(C_6H_5)_2$, and 1'- or 2'-(1',2',3',4'-tetrahydro)naphthylene;

25 R_3 is selected from the group consisting of hydrogen, C_1-C_{10} alkyl, $-CO(CH_2)_mCH_3$, $-CO_2CH_2Ar$, and $-COAr$;

n is 0, 1, or 2;

m is 0 thru 9;

Ar is selected from the group consisting of

(a) phenyl, 1- or 2-naphthyl, 3-indolyl, 2-, 3-, or 4-pyridinyl, or 1-imidazolyl,

(b) phenyl optionally substituted with 1 thru 5 -F or -Cl,

30 (c) phenyl optionally substituted with 1 thru 3 -Br, -I, $-CF_3$, $-R_4$, or $-OR_4$,

(d) phenyl substituted with $-COOR_4$, $-OCOR_4$, $-SO_2NH_2$, $-NHSO_2R_4$, and $-NHCOR_4$;

R_4 is C_1-C_5 alkyl;

provided, however, when R_1 is $-C_2H_5$, neither R_2 nor R_3 may be $-C_3H_7$;

35 and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein
R₁ is independent and selected from the group consisting of C₁-C₁₀ alkyl;
R₂ is selected from the group consisting of C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl,
-CH₂CH=CH₂, -CH₂CH₂OH, -CH₂(CH₂)_nAr, -CH₂CH₂OCH₂Ar, -CH(C₆H₅)₂ and 1'- or 2'-
5 (1',2',3',4'-tetrahydro)naphthylene; and
R₃ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl,
-CO₂CH₂Ar, and -COAr.

3. A compound according to claim 2 wherein
10 R₂ is selected from the group consisting of C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl,
-CH₂CH=CH₂, -CH₂CH₂OH, -CH(C₆H₅)₂, and 1'- or 2'-(1',2',3',4'-tetrahydro)naphthylene; and
R₃ is hydrogen.

15 4. A compound according to claim 3 selected from the group consisting of
2-(cyclohexylamino)-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester,
1-(diethoxyphosphinyl)-2-[(2'-hydroxy)ethylamino]ethyl phosphoric acid diethyl ester,
1-(diethoxyphosphinyl)-2-[2'-(1',2',3',4'-tetrahydro)naphthylamino]ethyl phosphoric acid
diethyl ester,
20 1-(diethoxyphosphinyl)-2-(2'-propen-1'-ylamino)ethyl phosphoric acid diethyl ester, and
1-(diethoxyphosphinyl)-2-(diphenylmethylamino)ethyl phosphoric acid diethyl ester.

5. A compound according to claim 2 wherein
R₂ is -CH₂(CH₂)_nAr;
25 R₃ is hydrogen;
Ar is selected from the group consisting of
(a) phenyl,
(b) phenyl substituted with 1 thru 5 -F or -Cl,
(c) phenyl substituted with 1 thru 3 -Br, -I, -CF₃, -R₄, or -OR₄,
30 (d) phenyl substituted with -COOR₄, -OCOR₄, -SO₂NH₂, -NHSO₂R₄, and
-NHCOR₄; and
R₄ is C₁-C₅ alkyl.

6. A compound according to claim 5 selected from the group consisting of
35 2-(benzylamino)-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester,

-21-

2-[(3'-fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester, and
(1*RS*,1'*R*)-1-(diethoxyphosphinyl)-2-[(1'-phenyl)ethylamino]ethyl diethyl ester.

7. A compound according to claim 6 which is 2-(benzylamino)-1-(diethoxyphosphinyl)ethyl
5 phosphoric acid diethyl ester.

8. A compound according to claim 6 which is 2-[(3'-fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl ester.

10 9. A compound according to claim 2 wherein

R_2 is $-CH_2(CH_2)_nAr$;

R_3 is hydrogen; and

Ar is selected from the group consisting of 1- or 2-naphthyl, 3-indolyl, 2-, 3-, or 4-pyridinyl, or 1-imidazolyl.

15

10. A compound according to claim 9 selected from the group consisting of
1-(diethoxyphosphinyl)-2-[(3'-pyridyl)methylamino]ethyl phosphoric acid diethyl ester,
1-(diethoxyphosphinyl)-2-[2'-(3'-indolyl)ethylamino]ethylphosphoric acid diethyl ester, and
1-(diethoxyphosphinyl)-2-[3'-(1'-imidazolyl)propylamino]ethyl phosphoric acid diethyl
20 ester.

11. A compound according to claim 10 which is 1-(diethoxyphosphinyl)-2-[(3'-pyridyl)methylamino]ethyl phosphoric acid diethyl ester.

25 12. A compound according to claim 2 wherein

R_2 is selected from the group consisting of $-CH_2CH=CH_2$, $-CH_2(CH_2)_nAr$, and
 $-CH_2CH_2OCH_2Ar$;

R_3 is selected from the group consisting of $-CO_2CH_2Ar$, $-CO(CH_2)_mCH_3$, and
 $-COAr$;

30 Ar is selected from the group consisting of

(a) phenyl,

(b) phenyl optionally substituted with 1 thru 5 -F or -Cl, and

(c) phenyl optionally substituted with 1 thru 3 -Br, -I, -CF₃, -R₄, or -OR₄,

R_4 is C₁-C₅ alkyl.

35

-22-


13. A compound according to claim 12 selected from the group consisting of
 2-[acetyl(3'-fluoro)benzylamino]-1-(diethoxyphosphinyl)ethyl phosphoric acid diethyl
 ester, and
 2-[benzyloxyformyl(2'-propen-1'-yl)amino]-1-(diethoxyphosphinyl)ethyl phosphoric acid
 5 diethyl ester.

14. A compound according to claim 1 wherein
 adjacent R₁ taken together are -CH₂(CH₂)_nCH₂- or -CH₂C(CH₃)₂CH₂-.

10 15. A compound according to claim 14 selected from the group consisting of
 5,5-dimethyl-2-[2-(3-fluorobenzyl)amino-1-[(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-
 yl)oxy]ethyl]-1,3,2-dioxaphosphorinane P,2-dioxide, and
 5,5-dimethyl-2-[2-(2-phenyl)ethylamine-1-[(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-
 yl)oxy]ethyl]-1,3,2-dioxaphosphorinane P,2-dioxide.

15

16. A process for making a compound of formula



wherein

30 R₁ is independent and selected from the group consisting of C₁-C₁₀ alkyl and -C₆H₅;
 adjacent R₁ taken together may be -CH₂(CH₂)_nCH₂- or -CH₂C(CH₃)₂CH₂-;
 R₂ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl,
 -CH₂CH=CH₂, -CH₂CH₂OH, -CH₂(CH₂)_nAr, -CH₂CH₂OCH₂Ar, -CH(C₆H₅)₂,
 and 1'- or 2'-(1',2',3',4'-tetrahydro)naphthylene;

35 R₃ is selected from the group consisting of hydrogen, C₁-C₁₀ alkyl,

-CO(CH₂)_mCH₃, -CO₂CH₂Ar, and -COAr;

n is 0, 1, or 2;

m is 0 thru 9;

Ar is selected from the group consisting of

5 (a) phenyl, 1- or 2-naphthyl, 3-indolyl, 2-, 3-, or 4-pyridinyl, or 1-imidazolyl,
 (b) phenyl optionally substituted with 1 thru 5 -F or -Cl,
 (c) phenyl optionally substituted with 1 thru 3 -Br, -I, -CF₃, -R₄, or -OR₄,
 (d) phenyl substituted with -COOR₄, -OCOR₄, -SO₂NH₂, -NHSO₂R₄, and

-NHCOR₄;

10 R₄ is C₁-C₅ alkyl;

provided, however, when R₁ is -C₂H₅, neither R₂ nor R₃ may be -C₃H₇;

comprising the steps of

reacting an epoxy ethane bisphosphonate with an amine at a sufficient temperature and for
a sufficient period of time to form reaction products comprising substantially compound of formula

15 IV;

extracting the reaction products; and

purifying the product via a chromatography procedure.

17. A process according to claim 16 wherein the temperature is between 0° C and 100° C and
20 the time is between 0.5 and 72 hours.

18. A process according to claim 17 wherein the temperature is between 0° C and 30° C and
the time is between 1 and 24 hours.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/04013

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 C07F9/40;	A61K31/66;	C07F9/58;	C07F9/572
C07F9/6506;	C07F9/6571		

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols	
Int.C1. 5	C07F ;	A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 015 370 (SYMPHAR S.A.) 17 September 1980 see the whole document ---	1
A	EP,A,0 186 405 (THE PROCTER & GAMBLE CO.) 2 July 1986 cited in the application ---	1

¹⁰ Special categories of cited documents :

- ^{"A"} document defining the general state of the art which is not considered to be of particular relevance
- ^{"E"} earlier document but published on or after the international filing date
- ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- ^{"O"} document referring to an oral disclosure, use, exhibition or other means
- ^{"P"} document published prior to the international filing date but later than the priority date claimed

^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^{"&"} document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

15 SEPTEMBER 1992

20.10.92

International Searching Authority

Signature of Authorized Officer

EUROPEAN PATENT OFFICE

BESLIER L.M.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9204013
 SA 61664

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 15/09/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0015370	17-09-80	GB-A-	2043073	01-10-80
		GB-A, B	2043072	01-10-80
		AU-B-	536326	03-05-84
		AU-A-	5495180	21-08-80
		CA-A-	1148561	21-06-83
		EP-A, B	0016310	01-10-80
		JP-A-	55111494	28-08-80
		JP-B-	1022277	25-04-89
		JP-C-	1541400	31-01-90
		JP-A-	55111495	28-08-80
		US-A-	4309364	05-01-82
		US-A-	4268507	19-05-81
		US-A-	4371527	01-02-83
		US-A-	4416877	22-11-83
		AT-B-	384224	12-10-87
		SU-A-	1207397	23-01-86
<hr/>				
EP-A-0186405	02-07-86	AU-B-	587001	03-08-89
		AU-A-	5153485	26-06-86
		JP-A-	61210033	18-09-86
<hr/>				